Population Health Sciences

You are here

Publications

Found 308 results

Author Title Type [ Year

]

Filters: First Letter Of Last Name is B [Clear All Filters]

2019

Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ et al.. 2019. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.. Cancer. 125(15):2561-2569.

Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ et al.. 2019. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.. Cancer. 125(15):2561-2569.

Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ et al.. 2019. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.. Cancer. 125(15):2561-2569.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2019. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2019. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2019. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.

Meinhofer A, Williams ARobin, Johnson P, Schackman BR, Bao Y. 2019. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 105:37-43.

Wen H, Hockenberry JM, Jeng PJ, Bao Y. 2019. Prescription Drug Monitoring Program Mandates: Impact On Opioid Prescribing And Related Hospital Use.. Health Aff (Millwood). 38(9):1550-1556.

Kapadia SN, Bao Y. 2019. Prescription painkiller misuse and the perceived risk of harm from using heroin.. Addict Behav. 93:141-145.

Kennel PJ, Kneifati-Hayek J, Bryan J, Banerjee S, Sobol I, Lachs MS, Safford MM, Goyal P. 2019. Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES).. BMC Cardiovasc Disord. 19(1):76.

Kennel PJ, Kneifati-Hayek J, Bryan J, Banerjee S, Sobol I, Lachs MS, Safford MM, Goyal P. 2019. Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES).. BMC Cardiovasc Disord. 19(1):76.

Sterling MR, Jannat-Khah D, Bryan J, Banerjee S, McClure LA, Wadley VG, Unverzagt FW, Levitan EB, Goyal P, Peterson JC et al.. 2019. The Prevalence of Cognitive Impairment Among Adults With Incident Heart Failure: The "Reasons for Geographic and Racial Differences in Stroke" (REGARDS) Study.. J Card Fail. 25(2):130-136.

Sterling MR, Jannat-Khah D, Bryan J, Banerjee S, McClure LA, Wadley VG, Unverzagt FW, Levitan EB, Goyal P, Peterson JC et al.. 2019. The Prevalence of Cognitive Impairment Among Adults With Incident Heart Failure: The "Reasons for Geographic and Racial Differences in Stroke" (REGARDS) Study.. J Card Fail. 25(2):130-136.

Casalino LP, Saiani R, Bhidya S, Khullar D, O'Donnell E. 2019. Private Equity Acquisition of Physician Practices.. Ann Intern Med. 171(1):78.

Brown B, O'Donnell E, Casalino LP. 2019. Private Equity Investment in Behavioral Health Treatment Centers.. JAMA Psychiatry.

Hood JE, Behrends CN, Irwin A, Schackman BR, Chan D, Hartfield K, Hess J, Banta-Green C, Whiteside L, Finegood B et al.. 2019. The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.. Int J Drug Policy. 67:9-18.

Hood JE, Behrends CN, Irwin A, Schackman BR, Chan D, Hartfield K, Hess J, Banta-Green C, Whiteside L, Finegood B et al.. 2019. The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.. Int J Drug Policy. 67:9-18.

Bhagwat P, Kapadia SN, Ribaudo HJ, Gulick RM, Currier JS. 2019. Racial Disparities in Virologic Failure and Tolerability During First-Line HIV Antiretroviral Therapy.. Open Forum Infect Dis. 6(2):ofz022.

Mehta BY, Ibrahim S, Briggs W, Efthimiou P. 2019. Racial/Ethnic variations in morbidity and mortality in Adult Onset Still's Disease: An analysis of national dataset.. Semin Arthritis Rheum.

Yin MT, RoyChoudhury A, Bucovsky M, Colon I, Ferris DC, Olender S, Agarwal S, Sharma A, Zeana C, Zingman B et al.. 2019. A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV.. J Acquir Immune Defic Syndr. 80(3):342-349.

Bond AM, Volpp KG, Emanuel EJ, Caldarella K, Hodlofski A, Sacks L, Patel P, Sokol K, Vittore S, Calgano D et al.. 2019. Real-time Feedback in Pay-for-Performance: Does More Information Lead to Improvement? J Gen Intern Med.

Shi Y, Liang D, Bao Y, An R, Wallace MS, Grant I. 2019. Recreational marijuana legalization and prescription opioids received by Medicaid enrollees.. Drug Alcohol Depend. 194:13-19.

Behrendt C-A, Kölbel T, Debus ESebastian, Rieß HChristian, Sedrakyan A. 2019. Reply.. J Vasc Surg. 69(4):1328.

Rosenkranz KM, Ballman K, McCall L, Kubicky CDai, Cuttino L, Le-Petross H, Hunt K, Giuliano A, Van Zee K, Haffty B et al.. 2019. Reply to "Can Patients with Multiple Breast Cancers in the Same Breast Avoid Mastectomy by Having Multiple Lumpectomies to Achieve Equivalent Rates of Local Breast Cancer Recurrence? Response to the Preliminary Alliance 11102 Trial Report". Ann Surg Oncol. 26(2):702.

Rosenkranz KM, Ballman K, McCall L, Kubicky CDai, Cuttino L, Le-Petross H, Hunt K, Giuliano A, Van Zee K, Haffty B et al.. 2019. Reply to "Can Patients with Multiple Breast Cancers in the Same Breast Avoid Mastectomy by Having Multiple Lumpectomies to Achieve Equivalent Rates of Local Breast Cancer Recurrence? Response to the Preliminary Alliance 11102 Trial Report". Ann Surg Oncol. 26(2):702.